Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2015 Q2- Text added to 2015 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
analyzed, antitoxin, Appraisal, aqua, AstraZenca, baseline, begun, bezlotoxumab, break, Clostridium, commonly, diagnostic, diarrhea, difficile, docetaxel, draft, enzyme, escrow, Excellence, expression, Fl, grasoprevir, Hyo, Inhibition, instability, Lifetec, MACE, Marizev, microsatellite, NICE, omarigliptin, PCV, play, pneumococcal, Pneumovax, polyvalent, proportion, qualifying, revealed, role, Savior, session, Stockpile, stream, strength, strongly, tissue, topline, TPS, true, virtually, week, weighted
Valuein 2015 Q2 filing- Value in 2015 Q3 filing
Original filings
Filing view